Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Localized Scleroderma Clear all
Completed Not applicable Interventional

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801
View directory record Official record
Conditions
Scleroderma, Keloids, Other Fibrosing Conditions
Interventions
German manufactured UVA1 light emitting device
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Jul 21, 2026, 6:11 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Sarilumab in Halting Progression of Morphea

NCT03679845
View directory record Official record
Conditions
Morphea, Plaque Form
Interventions
Sarilumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Early Phase 1 Interventional Results available

Molecular Effects of Topical Calcipotriene on Morphea

NCT02411643
View directory record Official record
Conditions
Morphea, Localized Scleroderma
Interventions
topical calcipotriene 0.005% ointment
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea

NCT01799174
View directory record Official record
Conditions
Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
Interventions
UVA-1 Phototherapy, Placebo
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Silicone-Associated Connective Tissue Diseases

NCT00001330
View directory record Official record
Conditions
Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

NCT01808937
View directory record Official record
Conditions
Scleroderma, Localized, Morphea, Frontal Linear Scleroderma en Coup de Sabre, Scleroderma, Circumscribed, Scleroderma, Linear
Interventions
Morphea
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

NCT00129428
View directory record Official record
Conditions
Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions
UVB Irradiation
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 21, 2026, 6:11 PM EDT
Active, not recruiting Not applicable Interventional

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

NCT04922736
View directory record Official record
Conditions
Scleroderma, Systemic, Morphea, Graft Vs Host Disease
Interventions
UVA-1 Phototherapy
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724
View directory record Official record
Conditions
Morphea, Scleroderma, Localized, Scleroderma
Interventions
FCX-013, veledimex
Genetic · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Not applicable Interventional

UVA1 Light for Scleroderma and Similar Conditions

NCT00476697
View directory record Official record
Conditions
Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
Interventions
German manufactured UVA1 emitting light system
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jul 21, 2026, 6:11 PM EDT
Active, not recruiting Not applicable Interventional

Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis

NCT06880627
View directory record Official record
Conditions
Scleroderma
Interventions
Brain Boost group, Waitlist group
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

NCT00812188
View directory record Official record
Conditions
Symmetric Limited Morphea
Interventions
Medium Dose UVA-1, High Dose UVA-1
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Outcomes Following Intralesional Corticosteroid Injections

NCT03630198
View directory record Official record
Conditions
Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions
Corticosteroid with lidocaine, Corticosteroid with normal saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

NCT03351114
View directory record Official record
Conditions
Morphea
Interventions
Crisaborole
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Jul 21, 2026, 6:11 PM EDT